Substitution of an SSRI With Bupropion Sustained Release Following SSRI-Induced Sexual Dysfunction
J Clin Psychiatry 2001;62:185-190
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: We examine changes in sexual
functioning and depressive symptoms in patients' transition from
a selective serotonin reuptake inhibitor (SSRI), which induced
both a therapeutic response and sexual dysfunction, to bupropion
sustained release (SR) over the course of an 8-week trial.
Method: The study included 11 adults (8 women
and 3 men) who had a DSM-IV diagnosis of major depressive
disorder in remission (Hamilton Rating Scale for Depression
[HAM-D] score < 11) and were receiving an SSRI. Depression
(using the HAM-D) and sexual dysfunction (using the Changes in
Sexual Functioning Questionnaire) were assessed at baseline, 2
weeks after bupropion SR was added to the current antidepressant
(combined treatment), 2 weeks after taper of the SSRI was
initiated and completed, and after 4 weeks of bupropion SR
monotherapy. T tests were performed to assess changes in
depression and sexual function.
Results: Patient participation dropped from the
initial group of 11 at week 2 to 9 at week 4 and to 6 by week 8.
Sexual functioning improved from week 0 (baseline) to week 2 and
from week 2 to week 4. The patients showed no significant change
in mean HAM-D scores in weekly comparisons during the study
period; 55% of patients completed the substitution without
significant adverse events or recurrence of depressive symptoms.
Conclusion: Bupropion SR as a treatment for
depression also alleviates sexual dysfunction due to SSRI
treatment. Results show that sexual functioning improves after
the addition of bupropion SR to SSRI treatment and continues to
improve, after discontinuation of the SSRI, with bupropion SR